Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of...
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Albert Einstein College of Medicine
- Registration Number
- NCT03685773
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
Regulation of Endogenous Glucose Production by Central KATP Channels
- Conditions
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 100
- Registration Number
- NCT03540758
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 153
- Registration Number
- NCT03510884
- Locations
- 🇪🇸
Investigational Site Number :7240003, Pamplona, Navarra, Spain
🇵🇱Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
🇲🇽Investigational Site Number :4840007, Oaxaca, Mexico
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT03510715
- Locations
- 🇩🇰
Investigational Site Number 2080001, Viborg, Denmark
🇪🇸Investigational Site Number 7240001, A Coruna, Spain
🇸🇮Investigational Site Number 7050001, Ljubljana, Slovenia
The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 150
- Registration Number
- NCT03163576
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT02890992
- Locations
- 🇨🇿
Investigational Site Number 2030002, Zlin, Czechia
🇺🇸Investigational Site Number 8400005, Charlotte, North Carolina, United States
🇺🇸Investigational Site Number 8400001, Cincinnati, Ohio, United States
Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Université de Sherbrooke
- Target Recruit Count
- 50
- Registration Number
- NCT02808182
- Locations
- 🇨🇦
centre de recherche du CHUS, Sherbrooke, Quebec, Canada
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 413
- Registration Number
- NCT02642159
- Locations
- 🇺🇸
Investigational Site Number 840-156, Tustin, California, United States
🇫🇮Investigational Site Number 246101, Oulu, Finland
🇺🇸Investigational Site Number 840-118, Los Angeles, California, United States
Niacin on Immune Activation : a Proof-of-concept Study
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 16
- Registration Number
- NCT02018965
- Locations
- 🇨🇦
Montreal Chest Institute, Montreal, Quebec, Canada
Assessment Of Vascular Health After Niacin Therapy (AVANT)
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 9
- Registration Number
- NCT02003638
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.